Related Experiment Videos
Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell
C Bain1, Y Merrouche, I Puisieux
1Department of Tumor Biology, Centre Léon Bérard, Lyon, France.
Abstract:
HLA phenotypes were characterized for 79 patients with metastatic renal cell carcinoma treated with interleukin 2 (IL-2). HLA-A32 was associated with a clinical response (P = 0.025). The frequency of HLA-A3 and/or A32 was higher among responders than non-responders (P = 0.008). Thus, these results suggest that, in vivo, IL-2 may enhance cellular-mediated immunity against a tumour antigen and that some MHC molecules are more efficient than others for endogenous tumour antigen presentation.
Insights
Human Leukocyte Antigen (HLA) phenotypes influence treatment outcomes for metastatic renal cell carcinoma patients receiving interleukin 2 (IL-2). Specific HLA types, particularly HLA-A3 and HLA-A32, correlate with improved clinical response to IL-2 therapy.
Area of Science:
- Immunogenetics
- Oncology
- Biochemistry
Background:
- Metastatic renal cell carcinoma (mRCC) is a significant health concern.
- Interleukin 2 (IL-2) is a known immunotherapy for mRCC.
- The role of Human Leukocyte Antigen (HLA) in IL-2 treatment response requires further elucidation.
Purpose of the Study:
- To investigate the association between specific HLA phenotypes and clinical response in mRCC patients treated with IL-2.
- To explore the potential mechanisms by which HLA molecules influence IL-2 immunotherapy efficacy.
Main Methods:
- Characterization of HLA phenotypes in 79 mRCC patients undergoing IL-2 treatment.
- Statistical analysis to correlate HLA types with clinical response rates.
- Comparison of HLA frequencies between responders and non-responders.
Main Results:
- A significant association was observed between HLA-A32 and clinical response (P = 0.025).
- Patients with HLA-A3 and/or A32 phenotypes showed a higher frequency among responders compared to non-responders (P = 0.008).
Conclusions:
- These findings suggest that specific HLA molecules, such as HLA-A3 and A32, may enhance the presentation of endogenous tumor antigens.
- IL-2 therapy might potentiate cell-mediated immunity against tumors, with HLA class I molecules playing a crucial role in this process.
- Certain MHC molecules demonstrate greater efficiency in presenting tumor antigens, impacting immunotherapy outcomes.